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ABSTRACT
REGRANEX (becaplermin[rhPDGF-BB]) Gel 0.01% is a topical gel used for the
treatment of chronic lower extremity diabetic neuropathic ulcers (8 weeks or longer). It
contains growth factors to aid in healing by promoting the formation of granulation tissue.
Becaplermin[rhPDGF-BB] is the only growth factor to show clinical efficacy and to be
approved by the FDA. The purpose of this study is to evaluate the effectiveness of this
topical gel to speed the closing of wounds and/or production of healthy granulation tissue.
To accomplish this evaluation, a chart review was done at Altru Health Systems. A
list of names of patients who have been treated at the wound clinic was attained and a chart
review was done on the basis of this list.

Eight patient charts, 4 of which received

REGRANEX and 4 that did not receive REGRANEX were reviewed.

Objective data

collected from the charts included: length, width and depth of the wound, percent
granulation tissue, location, cleansing and dressing of the wound. A statistical analysis was
performed to determine if REGRANEX was an effective wound topical gel. This study
demonstrated REGRANEX is associated with less eschar and therefore more granulation
tissue when viewed by the clinician. However, no significant difference was found with
statistical analysis. Improvement in the formation of granulation tissue is a plus for patients
with diabetes because it may prevent them from enduring the pain or other side effects that
go along with debridement.
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CHAPTER I
INTRODUCTION
REGRANEX (becaplermin) Gel 0.01% was approved by the Food and Drug
Administration in December 1997 as a treatment for lower extremity diabetic neuropathic
ulcers. 1 It is a topical gel that contains growth factors to promote the formation of
granulation tissue.
A common and serious complication of Diabetes Mellitus is lower extremity
diabetic ulcers, which can lead to amputations. 1 They are difficult to heal, may last for
months and often become infected because they remain open. Patients with diabetes have
decreased immunological systems that make it difficult for the body to fight infections.
Ulcers result from a variety of etiological factors. 2 Inability to heal is the main
identifying factor of a chronic ulcer. Minor trauma has been sited as a major contributing
factor to lower extremity ulcers and can lead to amputations. An example of this is
trauma related to foot wear.
Approximately 15% of people diagnosed with diabetes will develop a foot ulcer
during their lifetime. 1,2,3,4 Each year 2% to 3% of people with diabetes will develop a
foot ulcer.2 There are approximately 162,000 annual hospitalizations for foot ulcers and

46% of them have been diagnosed with diabetes. In 1990,2.8 million people with
diabetes were hospitalized. 1 Approximately 6% of those also had a diagnosis related to
lower extremity ulcers. Of patients hospitalized with diabetes, the length of stay was

59% longer if they also had a foot ulcer.2

1

If left untreated or treated incorrectly, ulcers may become infected and develop
gangrene which is the leading cause of amputations in a patient with diabetes. I ,3
Approximately 85% of all nontraumatic lower limb amputations start out as a foot ulcer.

2

Half of the amputations that are performed in the US are done on people with diabetes.
In people with diabetes, the annual amputation rate is 15 to 40 times higher than the rate
in nondiabetic people.1 Each year approximately 67,000 amputations are performed on
people with diabetes. I ,3,4,s Nearly half of those people will have further amputations of
the same leg or the opposite leg within 5 years. I ,4 Survival rate for individuals with
diabetes who have had a lower-limb amputation is 50% after the first 3 years and about
40% after 5 years. 1,3
Problem Statement
Social and economic burdens are associated with lower extremity ulcers.

3

Some

of these are loss of income and function and a decline in the patient's quality of life.
Some economic costs include costs of hospital care, doctor visits, operations,
rehabilitation, artificial limbs, and long-term care. 4 A rapid healing rate can have
important social and economic advantages for patients and their caregivers.

3

REGRANEX can provide a treatment for these ulcers which can decrease the cost by
healing ulcers faster. Since REGRANEX is a fairly new product, only a small amount of
literature has been published about the effectiveness of this topical ointment. This study
will also provide information about ulcers, healing, REGRANEX and a review of
previous clinical studies completed on REGRANEX.
Purpose of the Study
The purpose of this study is to evaluate the effectiveness ofREGRANEX
(becaplermin) topical gel to speed the closing of wounds and/or production of healthy
granulation tissue. A retrospective chart review of patients that received REGRANEX as
a treatment was performed to accomplish this purpose.
2

Significance of the Study
As Physical Therapists we are involved in the treatment of wounds. The
significance of this study is to make healthcare employees aware of this type of product
as another alternative in the treatment of lower extremity diabetic neuropathic ulcers.
This product may be able to improve patient's lives so they continue as a productive
citizen.
Research Questions
How does this growth factor effect wound healing?
What is a lower extremity diabetic neuropathic ulcer and how do you treat them?
What are the stages of wound healing and what is involved in each stage?
What is REGRANEX?
How safe and effective has REGRANEX been in previous clinical studies, including
animal and human studies?
Hypotheses
This Independent Study investigates the ability ofREGRANEX to speed the
closing of wounds and/or increase the production of granulation tissue. Healing is
defined as a decrease in the amount of percent eschar and area of the wound. Using
statistical analysis, is there a significant difference in healing between treatment groups
(REGRANEX and No REGRANEX) over a 3 month period?

3

CHAPTER II
LITERATURE REVIEW
There are five major factors which contribute to the development and persistence
of chronic lower extremity ulcers. 2,3 They are neuropathy, peripheral vascular disease,
edema, metabolic factors and infection. When these factors are combined with normal
mechanical stress during weight bearing, the lower extremity becomes vulnerable to the
development of ulcers.3
Neuropathy
Most patients with diabetic ulcers on the medial, lateral and plantar surfaces of the
foot have some degree ofneuropathy.2 Neuropathy effects more than 80% of patients
with diabetic foot ulcers. 1 Neuropathy is one of the causing factors in 60% oflower
extremity amputations. 1,4 Slow healing and resistance to traditional treatments are some
of the characteristics of diabetic neuropathic ulcers.3 Other characteristics include loss of
motor, sensory and autonomic neural function.1
Motor neuropathy will reduce or eliminate nerve signals that are sent to muscle to
keep proper tension and tone of the muscles. 4 Muscle weakness, atrophy and paresis are
some of the results of motor neuropathy.2 These structural changes make the foot
vulnerable to injury from wearing shoes which do not fit properly, trauma or repetitive
1

stress. Motor neuropathy can also cause foot deformities such as hammer toes,
Charcot's joint or neuro-osteoarthropathy. The imbalance of muscles can lead to cavus
or high arched foot. 6

4

The clawing of the toes can also cause alterations in the fat pads that protect the
metatarsal heads. I ,6 The muscles and fad pads may be thinner. 1 This makes the plantar
surface of the foot more susceptible to neuropathic ulcers especially under the metatarsal
heads. The toes are unable to bear weight when they are severely clawed and the weight
is then distributed to the metatarsal heads.6 It has been found that 90% of diabetic ulcers
occur on the foot where pressure from weight bearing is high.
Sensory neuropathy in a person with diabetes will produce a loss of protective
sensation. The person then becomes vulnerable to injury from pain, pressure and heat. 2
Minor trauma may not be felt by the patient and may go unnoticed for a period of time.
Examples of minor traumas leading to ulceration include foreign objects entering the
body while barefoot, shoes that do not fit properly, trauma from nail trimming, and burns
caused by hot water or warming feet on a radiator. 4 When sensation is lost, the person
may not even realize they have an ulcer. 6 The smell, blood stained sock or another
person's discovery may be the only way the person with diabetes becomes aware they
have an ulcer. They may also have a loss of proprioceptive sensation? With this loss,
the person is unable to judge what position their feet are in when they make contact with
the ground.
Autonomic neuropathy will alter blood flow in the peripheral vessels and decrease
perspiration. 1 These conditions along with warm and overly dry feet contribute to skin
breakdown, such as fissures and cracks. I ,2,6 The patient with diabetes has a distinctive
appearance to their foot with these neuropathic changes. 6 This includes a cavus (high
arched), dry, insensitive foot with dilated veins, good pulses, clawed toes, and
hyperkeratosis under the forefoot and heel.

5

Peripheral Vascular Disease
Peripheral Vascular Disease (PVD) or ischemia as the only factor in ulcers is rare
and occurs in about 10010 to 15% of patients with diabetic foot ulcers.

4

,6

It is common,

however, for patients to have some degree of decreased blood supply. About 15% to
20% have a mix of neuropathy and ischemia. PVD has been a factor in 62% of nonhealing lower extremity diabetic ulcers. 2 In 46% of amputations, PVD has been the
causing factor. PVD is four times higher in patients with diabetes than patients without
diabetes.

An early sign ofPVD is claudication which presents as leg pain on walking
distances? Patients with diabetes may not be able to describe the pain due to
neuropathy. For this reason they may not realize they have the PVD until tissue loss and
gangrene occur. Ninety percent of patients with diabetes have surgically correctable
occlusions.
Most ulcers due to PVD or ischemia occur in distal parts of the foot (i.e. the
toes).1 Patients with diabetes, who smoke, have hyperlipidemia, and hypertension are at
4

risk for atherosclerosis. The most commonly affected vessels are the superficial
femoral, tibial, and peroneal arteries.6 A single vessel is usually not the only
involvement. 2 ,6 In a person with diabetes and PVD the usual findings include a bounding
popliteal pulse and no pulse in the foot. 4
Peripheral Vascular Disease contributes to limb ulceration, gangrene and it delays
healing. 1,2 It increases the chances of acquiring an infection and decreases the body's
ability to fight infection by decreasing the oxygen, nutrients and antibiotics to the area.
In one study, it was shown that low (less than 30 mm Hg) transcutaneous oxygen tension
is a risk factor for foot ulcers. 1

6

Ulcers can occur with a constant low pressure applied over a length of time in an
ischemic foot.

6

Shoes and especially new shoes have been shown to cause ulcers due to

ischemia. People with diabetes are encouraged to wear new shoes for short periods of
time to prevent ulceration from happening. If an ischemic ulcer is formed, the blood
supply needed to heal the ulcer is greater then the blood supply needed for the intact skin.
Edema
Painful lower extremity edema may be present even in patients with neuropathy.2
It delays wound healing by decreasing the cutaneous blood supply. When the patient's
shoes do not allow for edema, the increased pressure makes their feet vulnerable to minor
trauma and ulcers. Treatment for edema includes control of infection, foot elevation,
compression stockings, elastic leg wraps and pneumatic compression devices.
Metabolic factors
Hyperglycemia, or high glucose levels, is common in patients with diabetes? The
effects of hyperglycemia influences the development of complications in diabetic
patients. These complications usually appear 15 years after hyperglycemia develops.
With hyperglycemia, sorbitol accumulates on nerves and attributes to neuropathy.
Another possible metabolic disturbance is in the glycation of proteins including collagen
and fibrin. Glycated proteins contribute to the microvascular and macrovascular
derangements of diabetes. This causes problems because an essential part of wound
healing is the synthesis of proteins such as fibroblasts and collagen.
Infection
Some factors that predispose patients to infection include poor granulation tissue
formation, prolonged persistence of abscesses and impaired wound healing? Abnormal
leukocyte function develops from high glucose and low oxygen levels, which increases a
patients risk for developing infections once the skin is broken. 1 The possibility of
infection is increased in areas where bacteria is high (i.e. the foot) . Some complications
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of infection that may develop include cellulitis, osteomyelitis and gangrene.S These often
lead to amputations.
Once infection has occurred, it can delay wound healing. It has been shown that
S

wounds with greater than 10 colonies of bacteria per gram of tissue have a lower healing
rate than those with fewer bacterial colonies. S Infection prolongs inflammation which
delays wound healing and contributes to chronic lower extremity diabetic ulcers. I
The Wound Healing Process
Normal wound healing happens in an orderly progression. I The injury occurs,
platelets arrive and release coagulation factors and growth factors. Homeostasis is
achieved by intense vasoconstriction for 5 to 10 minutes after injury. The wound is
7
cleared of dead tissue and foreign material. The wound is then ready for healing and
regeneration. There are 3 phases involved in normal wound healing: Inflammation,
Proliferation and Remodeling.l
The inflammation phase lasts 4 to 6 days after injury. I After the initial
vasoconstriction, vasodilation occurs to allow capillary permeability. 7 During this time
cells are recruited into the wound in an orderly fashion.I This is regulated by growth
factors, including platelet-derived growth factor (pDGF), which are released by the
platelets during coagulation. An influx of cells occur including neutrophils, macrophages
and fibroblasts. 1,7 Neutrophils are among the first to arrive. I Macrophages job is to kill
bacteria and ingest debris. There must be adequate tissue oxygen tension for the killing
of bacteria to occur.7 During the first 3 hours it is important to kill the bacteria to prevent
colonization. Macrophages are also a significant source of growth factors, such as PDGF
which playa key role in migration and activation of wound fibroblasts.I ,7
The proliferative phase begins 4-6 days after injury and lasts approximately 3
weeks. I Neovascularization occurs with the creation of an extracellular matrix, including
collagen, in the wound bed and epithelializtion. This phase is regulated by growth factors
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that are secreted by macrophages and fibroblasts. Fibroblasts produce substances
essential for wound repair. 7 They are the main source of collagen and wound connective
tissue. With no infection present, there is a continual decrease in the number of
inflammatory cells. 1
The remodeling phase begins 3-4 weeks after injury and it may continue for up to
2 years. 1,7 There is a balance of collagen deposition and degradation. There is a
reorganization of collagen fibers into a more organized structure. The collagen continues
to increase in tensile strength to withstand outside forces better than tissue prior to
remodeling. It eventually reaches a plateau which is only 80% as strong as normal tissue.
Impediments in Wound Healing
A chronic wound does not heal in an orderly progression and it has decreased
structural integrity.I,7 Skin ulcers are the most common chronic wound. Seventy percent
are due to pressure ulcers, diabetic foot ulcers and venous ulcers. Some factors which
impede healing include wound hypoxia, infection, presence of debris and necrotic tissue,
use of anti-inflammatory medications, a diet deficient in vitamins or minerals, or general
nutritional deficiencies, tumors, environmental factors and metabolic disorders.8 If
factors that impede wound healing are identified and controlled the wound will heal
faster. Studies have suggested that growth factors may stimulate healing. Growth factors
will work more efficiently in an environment free of these factors.
Wound hypoxia is the lack of oxygen to a wound. If there is only 30 to 40 mm
Hg of oxygen present, fibroblasts cannot replicate and collagen production is limited. 8
Wound hypoxia also leaves the wound vulnerable to bacteria. Possible causes of hypoxia
are scar tissue around the vessels which decrease diffusion of oxygen and nutrients. This
is the case with venous ulcers. Compressive therapy is used to treat this condition. In the
case of arterial insufficiency, treatment should include bypass grafting to increase the
amount of oxygen delivered to the area.
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Infection of a wound may decrease healing by releasing bacterial enzymes that
lessen the effects of fibrin and growth factors. S,8 All wounds have some bacteria present. 8

s

As stated before if there is more than 10 bacteria per gram of tissue present, the wound is
considered infected. When foreign debris is present in a wound, it does not take as many
bacteria to cause an infection. Bacteria are able to grow in the dead tissue. Debridement
is the main way to rid bacteria from the wound.
The use of anti-inflammatory drugs impedes wound healing. 8 Steroids, an
example of these, reduce wound healing by delaying inflammation. These effects can be
reversed by the administration of vitamin A. Nonsteroidal anti-inflammatory drugs also
impede wound healing. 8 Examples of these are aspirin and ibuprofen. They decrease
collagen production and the exact mechanism is unknown. Patients may need to change
pain medication until the wound shows signs of healing.
Tobacco is another impeding factor. 8 It increases hypoxia or decreases oxygen
to the wound. This occurs because the blood vessels are vasoconstricted. The patient
should be encouraged to limit tobacco use, including nicotine patches. Vitamin and
mineral deficiencies can also playa large role in impeding wound healing. If there is any
doubt as to the patient's nutritional status, supplements should be given.
Tumors should be considered as a differential diagnosis when evaluating a
wound. 8 Chronic skin cancer may result in tumors. A chronic wound is also at risk of
developing a Marjolin's ulcer which is aggressive squamous cell carcinoma. A tissue
biopsy should be performed if etiology is in doubt. The use of topical growth factors is
contraindicated if malignancy is present.
Some environmental factors which delay wound healing include pressure and
wound temperature. 8 Pressure must be relieved from the wound for it to heal. Wound
temperature of less than 30 degrees Celsius reduces the wounds strength after healing.
This is most likely due to vasoconstriction and decreased perfusion.
10

The metabolic disorder diabetes mellitus is one of the most common diseases in
patient with chronic wounds. 8 It impairs wound healing in all 3 phases. 1 Patients with
diabetes have a decreased inflammatory response, fibroblast proliferation, and collagen
accumulation, due to the high glucose concentrations.1,8 This decreases the tensile
strength of the wound. The healed wound will only be approximately 80% the original
strength which leaves them vulnerable to reinjury.l
Poor blood glucose control also impairs leukocyte function which increases
susceptibility to infection. 1,8 The macrophages' ability to kill bacteria is reduced and
makes chronic wounds more difficult to heal. 8 Disease management should be
implemented to prevent and heal ulcers. 1
Principles of Good Wound Care
Growth factors, such as rhPDGF, are more effective when combined with good
wound care. S Good wound care includes first assessing the wound and then determining
the extent of damage and the cause of the wound.l The most important components of
good wound care include debridement, infection control, pressure relief and maintaining
a moist wound bed. 1,3
In one study it was determined that debridement plays a vital role in the care of
chronic diabetic foot ulcers. S Debridement removes useless and dead tissue, which
includes callus, necrotic tissue and infected tissue.l This tissue impedes healing and
increases the risk of infection. Debridement has many advantages. S The examiner is able
to inspect the wound easier for infection. When removing calluses, excess pressure on
the wound may be relieved. The examiner can view any other sources of pressure (i.e.
bony prominences) and relieve the pressure point by removing it. Tissue with
excessively high bacterial count can be removed to increase healing.5,8 Aging or old
cells, which may have lost their ability to produce granulation tissue, can be removed
from the wound, which may stimulate the production and release of growth factors.
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Debridement also enhances the effects ofREGRANEX by aIlowing it access to viable
tissue and ceIl receptor sites.

1

Infection of the wound needs to be controlled due to the fact that it delays healing
by prolonging the inflammatory phase of wound healing, destroys healthy tissue and
prohibits new tissue from being deposited.1 Local infection can be prevented by sharp
debridement of infected tissue and applying saline moistened gauze dressings. If not
prevented, infection of the bone may occur which is known as·osteomyelitis. 4 The most
effective way to treat it, is by removing the infected bone. The patient wiIl require
antibiotics also.
Non-weight bearing is criticaIly important. 4 This should be maintained at all
times. The use of crutches, a walker, a wheelchair, walking casts, walking splints or
other devices can help with off-loading. 1,4 If complete off-loading is impossible then try
to relieve as much as is possible. 1 Off-loading should be continued for the rest of the
patient's life or the ulcer may reoccur.
It is important that the environment of the wound stay moist. 8 This prevents
1
further tissue damage. Wounds that are exposed to the air wiII have an increafie in tissue

necrosis and death of ceIIs.8 If eschar is formed and is not removed, epithelialization wiII
be impaired. Wet-to-dry dressings may be more harmful than beneficial. The dressing
may remove the margin where epithelial tissue is forming and therefore impair wound
healing. A moist environment can be achieved by changing the dressing 2 times per day
with a saline moistened gauze. 1
Platelet-derived Growth Factors (pDGF)
Growth factors were discovered in the late 1970's.9 Platelet-derived growth
factors (pDGF) were one of the first growth factors to be discovered and they play an
important role in wound healing. The phases of wound healing are initiated and
regulated by growth factors which include PDGF. 1 Platelet-derived growth factors are
12

synthesized and released at or near the wound site. A major source ofPDGF are
platelets. Macrophages are also a major source ofPDGF. Platelet-derived growth factors
are also produced by endothelial cells and under certain circumstances, fibroblasts. 10
All the primary healing components either synthesize and release or respond to
1

PDGF indicating how they are an integral part of the wound healing process. Some of
the activities that PDGF is involved in include cell mitogenesis and migration and
synthesis of protein and extracellular matrix components.

lO

Cell chemotaxis and

proliferation of inflammatory cells is stimulated by PDGF. 1,10 Platelet-derived growth
factors also stimulate macrophages to migrate to the wound site.in later stages of wound
healing. During the remodeling phase, PDGF plays an important role in synthesizing the
extracellular matrix such as collagen and stimulating the lysis of collagen.
PDGF-BB is a homodimer [two identical proteins (B) are formed together] of
PDGF held together by intermolecular disulfide bonds and is a dimeric protein. 1,3,10
Becaplermin [rhPDGF-BB], a recombinant human form ofPDGF, is produced by
inserting the human gene for the B chain ofPDGF into the yeast Saccharomyces

cerevisiae. It is purified and can than be applied to wounds. 1
Becaplermin (rhPDGF-BB) gel contains either 30 or 1OO~g ofbecaplermin per
gram of vehicle gel, sodium carboxymethyl cellulose aqueous-based gel or NaCMC. 1,3 It
is commercially known as REGRANEX (becaplermin) Gel 0.01 %.
REGRANEX (becaplermin) Gel 0.01%
REGRANEX is the first recombinant human growth factor to be developed and
approved by the FDA for the treatment of lower extremity diabetic neuropathic ulcers.1,9
The active ingredient is becaplermin.l REGRANEX is available in 2, 7.5 or 15 gram
multi-use tubes. It is a clear, colorless to straw-colored topical gel.
The REGRANEX gel is indicated for the treatment of lower extremity diabetic
neuropathic ulcers that extend into the subcutaneous tissue or beyond and have an
13

adequate blood supply.l,9 When it is used along with good wound care, REGRANEX has
been shown to increase the incidence of complete healing. The efficacy in the treatment
of other types of chronic, nondiabetic wounds is under investigation.
Contraindications for REGRANEX are few. Those patients with a known
hypersensitivity to any component of the gel should not be using this treatment. l It is
also not to be used with known neoplasms at the site of application. REGRANEX should
not be used on wounds that close by primary intention (surgical incisions). The reason is
that REGRANEX is a nonsterile, low bioburden, preserved product.
REGRANEX has an excellent safety profile. l Although.safety and effectiveness
have not been established in patients below 16 years of age. In a study in mice, toxicity
was not observed at a significant level following a single IV dose of3 mg/kg
becaplermin.11 In another study, systemic toxicity was not evident in rabbits or monkeys
following multiple doses ofbecaplermin. The rabbits also did not show significant
dermal irritation. No cardiographic abnormalities were seen in monkeys following high
doses ofbecaplermin.
In a bacteria and mammalian cell mutation assay results indicated that
becaplermin was not mutagenic. 11 Becaplermin did not induce unscheduled DNA
synthesis and it is not considered a reproductive genotoxin or a systemic carcinogen. The
study concluded that based on the results, the potential for becaplermin to cause adverse
reactions after being applied to open wounds is insignificant.
Similar incidence of adverse reactions such as infection, cellulitis and
osteomyelitis occurred in patients receiving REGRANEX, placebo gel and good wound
care alone.1 Erythematous rashes occurred in 2% of patients treated with REGRANEX
gel or placebo gel and none in patients receiving good wound care alone. Patients who
were treated with REGRANEX did not develop antibodies against becaplermin.
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It is not known ifREGRANEX can cause fetal harm or be excreted in milk so
1

caution should be used when administering in these situations. It is also not known if
REGRANEX interacts with other topical medications that have been applied to the ulcer
site. This has not been studied.
Preclinical Animal Studies
Animal studies have shown that rhPDGF-BB accelerates the wound healing
process by promoting the formation of granulation tissue. 1.9.10 Within these studies
epithelialization, contraction, granulation tissue formation, and wound strength were
evaluated. 9
In a guinea pig partial-thickness model it was found that becaplermin had no
consistent effect on epithelialization and contraction and these parameters were thrown
out of later studies. 9 However, becaplermin was found to be effective in increasing the
granulation tissue thickness of the wound bed by at least 2- to 3-fold over vehicle control
in this model. The efficacy ofbecaplermin was reduced in shallow wounds with many
hair follicles that epithelialize quickly suggesting that the effects diminishes as the
wounds remodel.
In the pig full-thickness model effects ofbecaplermin on granulation tissue was
evident and statistically significant at day 7, but diminishes by day 14, when
epithelializtion was nearly complete.9 The conclusion of this study was that PDGF has
been repeatedly shown to enhance the formation of granulation tissue in animal studies
but its effects on epithelialization and wound contraction has been variable. Becaplermin
was developed on the assumption that by stimulating a rich vascular wound bed it would
promote epithelial ingrowth. One must take into consideration that no animal study will
completely mimic a chronic human wound.
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Dosage and Administration
The amount ofREGRANEX that should be applied to a wound depends on the
size of the ulcer. 1 The first step in deciding the dosage is measuring the greatest length
and the greatest width. These two numbers are then multiplied. If they were measured in
inches then that number is multiplied by 0.06 and if it is measured in centimeters, it is
divided by 4. In other words, each square inch of ulcer surface requires approximately
2/3 inch length ofREGRANEX gel from a 15 gram tube. Each square centimeter of
ulcer requires 0.25 cm length ofREGRANEX gel from a 15 gram tube.
Once the dose is determined REGRANEX gel should be. squeezed from the tube
onto a clean measuring surface i.e. wax paper. 1 The gel can then be applied with a
tongue blade or cotton swab over the ulcer in a thin, continuous layer approximately 1116
inch thick. It is then covered with saline moistened gauze dressing and left for 12 hours.
After that time it is rinsed with saline or water to remove excess gel. The ulcer is then
covered with a saline moistened gauze without application ofREGRANEX.
REGRANEX is to be applied one time per day and excess application has not been
proven to be beneficial. The amount ofREGRANEX to be applied should be
recalculated weekly or biweekly. Use ofREGRANEX should be reassessed if the ulcer
does not show a decrease in size by 30% after 10 weeks of application or complete
healing after 20 weeks. REGRANEX must be stored in the refrigerator.
Clinical Efficacy
Four randomized controlled studies were completed on REGRANEX. There
were 922 patients which participated in the studies. 1 The first study was completed on
118 patients with diabetic neurotrophic foot ulcers.5 They were treated with either
REGRANEX Gel 0.003% or a placebo gel. 1 The criteria for the study included all
patients free of infection, all ulcers were secondary to neuropathy, had adequate arterial
blood supply and wounds were present for at least 8 weeks. 5 Patients were excluded if
16

they had poor diabetes control, renal failure, abnormal liver function and no patients with
exposed bone were included in this study. Patients were treated until the ulcer was
completely healed or up to 20 weeks. Healing was defined as 100% closure.
All the patients had aggressive, sharp debridement of callus and necrotic tissue
down to bleeding tissue initially and then as needed throughout the study.5 The mean
percentage of office visits where debridement was performed was 46.8% for
REGRANEX and 48.0% for the placebo gel. The results of this study included 48% of
patients treated with REGRANEX healed and 25% of patients treated with the placebo
gel healed during the 20 weeks. For the REGRANEX group, the site with the highest
debridement rate had the highest healing rate and the site with the lowest debridement
rate had the lowest healing rate. For the placebo group, the site with the lowest
debridement rate had the lowest healing rate but at the sites with higher debridement
there was no relationship between healing and frequency of debridement.
In a second study 382 patients were treated with either REGRANEX gel 0.01%,
REGRANEX gel 0.003% or a placebo gel. 3 The incidence of complete healing for the
REGRANEX 0.01% group was 50%, REGRANEX 0.003% group was 36% and the
.placebo group was 35%. Treatment with REGRANEX 0.01% increased the incidence of
complete healing by 43% when compared with the placebo group. The study found that
there was no statistically significant difference in the incidence of complete healing
between patients receiving REGRANEX 0.003% and the placebo group.
There were 3 groups with 172 patients in the third study.12 The groups were good
wound care alone, good wound care plus NaCMC (Sodium Carboxymethyl cellulose) gel
and good wound care plus becaplermin gel 100

~g/g,

NaCMC is the vehicle gel. It was

found that the incidence of complete healing for the good wound care alone was 22%,
NaCMC group was 36%, and becaplermin group was 44%.
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The fourth study included 250 patients. 1 The 2 groups in this study were
REGRANEX gel and good wound care alone. The incidence of complete healing for the
REGRANEX group was 36% and for good wound care alone was 32%. These were not
statistically different in this study.
There was a 3 month follow-up study completed for the incidence of ulcer
recurrence. l It was found that 30% of patients had an incidence of ulcer recurrence. This
demonstrates that the ulcers were of comparable durability across all treatment groups.
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CHAPTER III

METHODOLOGY
A review of medical charts was completed at AItru Wound Clinic to determine if
REGRANEX is effective in speeding the closing of wounds and/or production of healthy
granulation tissue. AItru Wound Clinic was contacted for permission to review charts on
adult patients (18 years or older) who had been treated for lower extremity ulcers.
Subjects
Medical charts selected included patients who had received REGRANEX as a
treatment for lower extremity ulcer(s) and patients who did not receive REGRANEX as a
treatment but had a similar medical background. A description of demographic data on
subjects included in this study is summarized in Table 1.
Subjects were assigned to 2 separate groups on the basis of treatment. The
treatment group received REGRANEX application 1 time per day while the control group
did not receive REGRANEX. Both groups received normal clean wound care.
Information on the treatment they received was located in their medical charts.
Approval and Consent forms
Approval was obtained prior to any coIIection of data. This was accomplished
by completing a University of North Dakota (UND) Human Subject Review Form
(Appendix A) and submitting it to the UND Institutional Review Board. Approval was
also obtained from AItru Health Systems Institutional Review Board.

19

Table 1. Demographic data of patients used in chart review.

ID#
1

SEX
MIF
F

DATE
OF
BmTH
06/05111

REGRANEX/
NO
REGRANEX
REGRANEX

2

M

12/28/26

No
REGRANEX

3

F

08/09/42

No
REGRANEX

4

F

11114/60

No
REGRANEX

5

F

07/07/24

No
REGRANEX

6

F

06/21/38

REGRANEX

8

F

04/24/37

REGRANEX

9

M

08/03/27

REGRANEX

PAST MEDICAL
HISTORY
Cellulitis

DIAGNOSIS
Venous stasis ulcer,
dermatitis, venous
insufficiency
Diabetes, severe
Carotid occlusive
disease, AAA, gout, neuropathy, PVD,
renal insufficiency, coronary disease,
COPD, obesity
heart bypass
Diabetes, chronic
CHF, renal
calcaneal
insufficiency, (B)
osteomyelitis,
HTN,
carotid artery
obesity, asthma, good
stenosis
circulation
Good arterial
Ulcer left foot,
Diabetes, peripheral
circulation
neuropathy, HTN,
asthma
Diabetes, Neuropathy
Head and neck
cancer, normal
circulation,
claudication
Diabetes, severe
Ovarian cancer,
neuropathy, Charcot
cellulitis
foot
Neuropathic, chronic
HTN, orthotic,
and recurrent left heel
normal arteriole
circulation
ulcer
Diabetes, neuropathy,
Smoker, HTN
pressure ulcer left
heel, arteriole
insufficiency
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Instrumentation
A data collection tool (Appendix B) was used to gather demographic data,
location of wound, treatment procedure, length, width, depth and percent granulation and
other information about the patient and their wounds.
Procedure
Upon completion of the approval process, a list of names was compiled by the
Altru Wound Clinic. This list included subjects who had received REGRANEX and
subjects who did not receive REGRANEX as a treatment but had similar medical
backgrounds. Altru Medical Records department was then contacted and given the list of
names. The chart review took place at the medical records department.
Data was gathered from the Altru Initial Wound Documentation Record and the
Altru Wound Care Flowsheet (Appendix C) in the chart using the data collection tool
(Appendix B) previously described under instrumentation.
Data Analysis
The independent variables used in this study included treatment, REGRANEX or
no REGRANEX, and time (Start, Month 1, Month 2, Month 3). The dependent variable
used was size of wound (area) and the percentage of eschar. Data collected will be
analyzed with the Statistical Package for Social Sciences (SPSS) version 8.0 software to
demonstrate if there is significant improvement in size of ulcer when compared with the
nominal data of treatment, time and measure.13 An alpha level of .05 will be used during
analysis.
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CHAPTER IV
RESULTS
Eight charts were reviewed at Altru Health Systems, one was eliminated due to
the type of ulcer and the patient's medical history. A total of 12 wounds were evaluated
from which data collected included the percentage of eschar and wound size (area =
length x width). This information was utilized to evaluate the effectiveness of
REGRANEX (becaplermin) gel 0.01% to speed the closing of wounds and/or production
of healthy granulation tissue. The length and width of the ulcers were measured in
centimeters and are recorded in Tables 2 and 4 for patients who were treated with
REGRANEX. Infonnation for those individuals who did not receive REGRANEX can
be found in Tables 3 and 5. Percentage of eschar can be found in Tables 6 and 7. Data
was analyzed on SPSS using a two-way analysis ofvariance.13

The statistical analysis for percent eschar is as follows:
•

An interaction occurred between treatment and time. F(3,31) = 3.417; P < 0.05;
P = 0.03

•

Treatment has a significant effect on percent eschar. F(1,31) = 11.371; P < 0.05;

P = 0.002
•

Time has a significant effect on percent eschar. F(3,31) = 5.810; P < 0.05; P = 0.003

When looking at time as a simple main effect for percent eschar:
•

There was a significant difference between times for percent eschar with no
REGRANEX. F(3,31) = 4.829; P < 0.05; P = 0.015. The significant difference was
between initial evaluation and month 2.
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Table 2. Length of ulcers at each time interval measured in centimeters in patients
treated with REGRANEX.
LOCATION OF
ID#
ULCER
1 Right medial ankle
1 Right lateral ankle
6 Right foot plantarlateral
6 Right foot plantarmiddle
6 Right foot plantarmedial
8 Left heel
9 Left heel

ST

1

2ND

3 lW

INITIAL
3.3
1.5
0.7

MONTH
3
1.5
0.6

MONTH
2.9
1.4
0.2

MONTH
2.8
1.3
Healed

0.3

0.2

Healed

Healed

3.5

2.7

2.3

2.1

2.4
1.2

2.7
0.13

2.8
0.4

2.8
0.2

Table 3. Length of ulcers at each time interval measured in centimeters in patients not
treated with REGANEX.
LOCATION OF
ID#
ULCER
2 Right great toe
2 Left great toe
3 Right heel plantar
4

Left great toe-base

INITIAL
1
2.1
3.4

0.3

Left great toe-lateral
0.3
5 Right heel-medial
2
5 Right great toe
0.2
* These patients did not return to the physician.
4
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IIH

2ND

MONTH
0.6
1.0
Not
measured
Not
measured
0.2
2
0.1

MONTH
0.2
0.8

3 lW
MONTH

*

*
*
*

0.3

0.6

Healed

Healed

*
*

*
*

Table 4. Width of ulcers at each time interval measured in centimeters in patients treated
with REGRANEX.
LOCATION OF
ULCER
ID#
1 Right medial ankle
1 Right lateral ankle
Right foot plantar6
lateral
6
Right foot plantarmiddle
Right foot plantar6
medial
8
Left heel
9 Left heel

ST

1

2ND

3 IW
MONTH

INITIAL

MONTH

MONTH

1.3
1.1
1.2

1.1
1.1
0.7

1.1
1.1
0.5

Healed

0.3

0.2

Healed

Healed

3.4

2.9

1.4

1.4

2.1
0.4

2.4
0.5

2.5
0.4

2.5
0.4

1.2
1.0

Table 5. Width of ulcers at each time interval measured in centimeters in patients not
treated with REGRANEX.
LOCATION OF
ID#
ULCER
2 Right great toe
2 Left great toe
3 Right heel plantar

4

Left great toe-base

1M
INITIAL

MONTH

0.7
1.5
3.4

0.4
1.4
Not
measured
Not
measured

4.7

4
5
5

Left great toe-lateral
2.7
Right heel-medial
1.0
Right great toe
0.2
* These patients did not return to the physician.

24

0.2
1.3
0.1

2NJJ
MONTH
0.3
1.1

3 IW
MONTH

*

*
*
*

2.5

0.7

Healed

Healed

*
*

*
*

Table 6. Measurement of percent (%)eschar and necrotic tissue at each time interval in
patients treated with REGRANEX.

LOCATION OF
ULCER

ID#
1 Right medial ankle
1 Right lateral ankle
6 Right foot plantar-

6
6
8
9

lateral
Right foot plantarmiddle
Right foot plantarmedial
Left heel
Left heel

ST

1

2ND

3 KD

INITIAL
20
50
20

MONTH
20
30
0

MONTH
20
30
10

MONTH
20
30

Not
measured

Not
measured

Healed

Healed

20

0

0

0

0
10

0
0

0
0

0
20

Healed

Table 7. Measurement of percent (%) eschar and necrotic tissue at each time interval in
patients not treated with REGRANEX.

ID#
2
2
3
4
4

LOCATION OF
ULCER
Right great toe
Left great toe
Right heel plantar
Left great toe-base
Left great toe-lateral

ST

1

INITIAL
50
90
60
20

MONTH
60
85
90
20

Not
measured

10

5
5

Right heel-medial
80
Right great toe
100
* These patients did not return to the physician.
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70
10

2ND

3 KD

MONTH
10
30

MONTH

*

*
*
*

Pale pink
callous
Callous
Healed

Not
measured
Healed

*
*

*
*

•

There was no significant difference between times for percent eschar with
REGRANEX. F(3,31) = 2.554; P < 0.05; P = 0.097

When looking at treatment as a simple main effect for percent eschar:
•

There was a significant difference in percent eschar at initial evaluation between
treatment groups. F(1,31) = 12.224; P < 0.05; P = 0.008

•

There was a significant difference in percent eschar at month 1 between treatment
groups. F(1,31) = 5.136; P < 0.05; P = 0.050

•

There was no significant difference in percent eschar at month 2 between treatment
groups. F(1,31) = 1.464; P < 0.05; P = 0.266

•

There was no significant difference in percent eschar at month 3 between treatment
groups. F(1,31) = 0.357; P < 0.05; P = 0.576

The statistical analysis for size (area in centimeters) is as follows:
•

No interaction occurred between treatment and time. F(3,30) = 0.068; P < 0.05;
P = 0.976

•

Treatment had no significant effect on size. F(1,30) = 1.952; P < 0.05; P = 0.173

•

Time had no significant effect on size. F(3,30) = 0.813; P < 0.05; P = 0.497

When looking at main effects only without a two way interaction:
•

There was no significant difference in size (area in centimeter) between treatments.
F(1,30) = 2.126; P < 0.05; P = 0.154

•

There was no significant difference in size (area in centimeter) between time.
F(3,30) = 0.942; P < 0.05; p = 0.431

When looking at time as a simple main effect:
•

There was no significant difference for size (area in centimeter) with no
REGRANEX. F(3,30) = 1.014; P < 0.05; P = 0.416
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•

There was no significant difference for size (area in centimeter) with REGRANEX.

F(3,30) = 0.211; P < 0.05; P = 0.887

. . 0 f percent eschar 0 f each treatment ~roup .
T a ble 8 The mean and standard deVlatlOn

Group

INITIAL

MONTH 1

MONTH 2

MONTH 3

REGRANEX

12.5 ± 9.6

O±O

2±4.5

4±8.9

Non-REGRANEX

66.7 ± 29.4

37.9 ± 32.6

10±14.1

O±O

Table 9. The mean and standard deviation of size (area in centimeters) for each
treatment group.

Group

INITIAL

MONTH 1

MONTH 2

MONTH 3

REGRANEX

3.7±5.0

3.0 ± 3.9

2.1±3.1

2.0±3.1

Non-REGRANEX

2.8 ±4.0

0.9 ± 1.1

0.4 ± 0.5

0.2 ± 0.3

When looking at Table 10, the number of wounds having 0% eschar increased for
the REGRANEX group.

Table 10. Total number of wounds with 0% eschar at each time interval
Group

INITIAL

MONTH 1

MONTH 2

MONTH 3

REGRANEX

1

4

4

4

Non-REGRANEX

0

2

2

0
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When looking at Table 11, the total number of healed wounds based on the area at
Month 3 was 2 with REGRANEX and 1 with No REGRANEX.

Table 11. Total number of healed wounds based on size (area in centimeters) at each
time interval.
Group

INITIAL

MONTH!

MONTH 2

MONTH 3

REGRANEX

0

0

1

2

Non-REGRANEX

0

0

1

1
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CHAPTER V
DISCUSSION
Depth measurements were not included in this study due to the fact that some of
the measurements were either not taken or not recorded in the charts. It was felt that the
missing information would not give accurate statistical data so therefore it was not
include in this study.
It was also felt that the subject with the ID number of 1 should not be included in

the statistical analysis. This subject's ulcer was diagnosed as a venous stasis ulcer. Since
REGRANEX is approved for lower extremity diabetic neuropathic ulcers, it was decided
that only subjects who carried this diagnosis would be included in the study.
The treatment groups were very different from the start. This makes it difficult to
compare them. The mean of percent of eschar changed from 66.667% to 0% for the nonREGRANEX group and 12.5% to 4% for the REGRANEX group. The mean size (area
in centimeters) changed from 2.81 to 0.21 for the non-REGRANEX group and 3.67 to
2.004 for the REGRANEX group. This indicates that the non-REGRANEX group had
more eschar and the area was smaller than the REGRANEX group. It also shows that
size of the wound changed more with the non-REGRANEX group then with the
REGRANEX group.
The statistical analysis appears to demonstrate that REGRANEX was not
effective in this retrospective clinical trial. An interaction did occurred between
treatment and time for percent eschar. However it was for the non-REGRANEX group
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and it occurred between initial evaluation and Month 2. There was also a significant
difference for percent eschar at initial evaluation and Month 1 between treatment groups
but again these groups were very different from the start.
Even though it was not shown to be very effective, the REGRANEX group has an
overall decrease in eschar tissue and increase in granulation tissue when compared to the
non-REGRANEX group when looking at Table 12 in Chapter IV. At initial evaluation
the REGRANEX group had 1 patient with 0% eschar and at Month 1 there were 4
patients with 0% eschar. This indicates that REGRANEX does increase granulation
tissue. This is consistent with the literature. REGRANEX has been proven in previous
studies to increase the formation of granulation tissue.(A,I,N)
When looking at size (area in centimeters), there was no interaction that occurred
between the time and treatment groups. No significant differences were found when
looking at the main effects and simple main effects for either treatment group or time.
Limitations
There were several limiting factors to this study. Since this study was done in a
small community, one limitation of this study was the insufficient number of subjects
who received REGRANEX. Statistical analysis was done on 7 subjects with a total of 12
ulcers. A larger group would have given more accurate statistical outcomes. A minimum
of25 to 30 randomly selected charts should be used for increased accuracy.
There were some limiting factors because this was a chart review. They included
interrater reliability and validity, patient compliance and the treatment of nonREGRANEX patients. Interrater reliability and validity was impossible to achieve due to
the varied number of people who did the measuring and treating of the ulcers. Patient
compliance was also a factor. There is no access to patients when doing a chart review so
I was unable to check to see if patients were following their prescribed treatment. The
treatment regimen for non-REGRANEX varied and this can affect healing. Another
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limiting factor was that some data was missing from the charts. This limited the amount
of statistical analysis that could be completed on this study.
Possible Future Studies
Since there is a difference in literature as to the effectiveness ofREGRANEX, it
should be investigated further. Future studies could also focus on venous stasis ulcers
and pressure ulcers to see how effective REGRANEX is in these cases. Currently there is
no literature available on how effective REGRANEX may be in these areas.
Conclusion
Since Physical Therapists are involved in wound care, I feel it is important for
them to have information on the products they may be using in the clinic. This way they
can make their own personal decision about the product. This study gives them a
background on what REGRANEX is and investigates how and if it works. This study
demonstrated REGRANEX is associated with less eschar and therefore more granulation
tissue when viewed by the clinician. However, this was found to be not significant with
statistical analysis. REGRANEX does not increase the incidence of healing when
compared with patients who have not received REGRANEX as a treatment.
Improvement in the formation of granulation tissue is a plus for patients with diabetes
because it may prevent them from enduring the pain or other side effects that go along
with debridement. The use of growth factors is good in theory but further investigation is
warranted further, with a larger group, as to whether or not it works in the clinic.
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APPENDIX A

APPLICATION TO CONDUCT RESEARCH
AT ALTRU HEALTH SYSTEM FACILITIES
Any researcJrer proposing to conduct researcJr using patients, staff, or records ofAltr" Health System
must obtain organizational approval as weU as IRB approvaL Complete thi& applicationform and
submit it along with a briefsummary ofthe study, including consent and instruments to: V"uginia
Esslinger, MS, RN. Altru Health Research Center, P.O. Box 6002, Grand Forks, ND 58206-6002

~Altru physician/staff member
~Student

Department
Advisor
Da\/f . "Qe .lIiI\A . M0. pr
Relationship to Altru, if any__J_'_ _ _ _ _ _--=,..---.,---,__
" Coursework __Thesis _ _Dissertation 20ther ~+

_ _Faculty

College/Department'--_ _--""_ _ _ _ _ _ _ _ _ _ _ __
Relationship to Altru, ifany_ _ _ _ _ _ _ _ _ _ _ _ __

_ _Other

_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __
Position'-_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __
Relationship to Altru, ifany_ _ _ _ _ _ _ _ _ _ _ _ __
O~ruriution

Please answer the following questions:
1. Describe the nature and e.xtent of involvement expected of Altru staffwith your project (include
specific staff members by name and/or title, specific activities requested of them and an estimate of
the amount of their time that would be required).

See.. attachetL Ahru-s ·
2. Describe the nature of patient contact required by your project, if applicable (i.e. access to
medical records, patient interviews, etc.)
(over)
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1. I have already spoken with Pat Guthmiller,RN about this project. Once this project is
approved I will need to get the chart numbers of the patients from her. Medical records

will then be involved to retrieve the charts for me. The remaining part of the study will
involve getting information from patient's charts by myself.

2. The extent of patient contact will be done through the access of their medical charts.

3. All patient's charts will be given an anonymous code. These along with all the
information from this study will be kept in a locked cabinet in Room 1531 of the
University of North Dakota Physical Therapy Department for 3"years and will be
destroyed after this time.

4. I will require access to patient's medical records and the information will be taken
from these charts.

5. The only space required will be space to review charts.

6: Start: 6/1/99
Completion at Altru: 10/1/99
Completion of project: 12/99

· 7. None
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_EXPEDITED REVIEW REQUESTED UNDER ITE"4_ (NUMBER[S]) OF HHS REGULATIONS
-2LEXEMPT REVIEW REQUESTED UNDER ITEM...!1.- (NUMBER[S]) OF HHS REGULATIONS
UNIVERSITY OF NORTH DAKOTA HUMAN SUBJECTS REVIEW FORM
FOR NEW PROJECTS OR PROCEDURAL REVISIONS TO APPROVED
PROJECTS INVOLVING HUMAN SUBJECTS

PRINCIPAL
INVESTIGATOR:
Melissa Woodl Dave Reiling
TELEPHONE: 795-9285
DATE: 5/10/99
ADDRESS TO WHICH NOTICE OF APPROVAL SHOULD BE SENT: UND, Physical Therapy, Box 9037, G.F., ND 58202-9037
PROPOSED
SCHOOL/COLLEGE:_U::.N:.=;DIM:...:....:,:e:.::d.::::lc!!!ln::..e_ _ _ _ _ _ DEPARTMENT: PhysIcal Therapy
PROJECT DATES: 6/1/99 to
5/1/00

PROJECT TITLE: Evaluation of the effectiveness of Regranex (becaplermln) on treatment of wounds
FUNDING AGENCIES (IF APPLICABLE): _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __
TYPE OF PROJECT (Check ALL that iPPIy):
DISSERTATION OR
..lL NEW PROJECT
CONTINUATION
RENEWAL
THESIS RESEARCH
_X_ STUDENT RESEARCH PROJECT
_

CHANGE IN PROCEDURE FOR A PREVIOUSLY APPROVED PROJECT

DISSERTATIONITHESIS ADVISER, OR STUDENT ADVISER:
PROPOSED PROJECT:
TION

Dave ReDIng, MS, PT
INVOLVES NON-APPROVED
INVOLVES A
USE OF DRUG
_X_COOPERATING INSTITU-

INVOLVES NEW DRUGS (IND)

IF ANY OF YOUR SUBJECTS FALL IN ANY OF THE FOLLOWING CLASSIFICATIONS, PLEASE INDICATE THE CLASSIFICA·
nONeS):
_

MINORS « 18 YEARS)

PREGNANT WOMEN

PRISONERS

ABORTUSES

MENTALLY DISABLED
_

FETUSES

MENTALLY RETARDED

UND STUDENTS (> 18 YEARS)

IF YOUR PROJECT INVOLVES ANY HUMAN TISSUE, BODY FLUIDS, PATHOLOGICAL SPECIMENS, DONATED ORGANS,
FETAL MATERIAL, OR PLACENTAL MATERIALS, CHECK HERE _ __
IF YOUR PROJECT HAS BEEN\WILL BE SUBMITTED TO ANOTHER INSTITUTIONAL REVIEW BOARD(S),PLEASE LIST NAME OF
BOARD(S):
Status: . _ SubmItted; Date
_ Approved; Date
PendIng
1. ABSTRACT: (LIMIT TO 200 WORDS OR LESS AND INCLUDE JUSTIFICATION OR NECESSITY FOR USING HUMAN SUBJECTS.
The purpose of this case study Is to revIew the effects of Regranex (becaplermln). Regranex Gel has been used on lower
extremIty dIabetic neuropathIc ulcers whIch extend Into the subcutaneous tissue or beyond and the blood supply has not been
compromised. Regranex contaIns a human platelet-derived growth factor which promotes the proliferation of cells for healing.
From prevIous studIes, Regranex has been shown to Increase healing. I am goIng to use patient medIcal records from Altru to
analyze how effective Regranex has been In clInIcal use when compared wIth patients who have not received Regranex. SubJects:
50 MedIcal Charts will be revIewed from Altru HospItal Systems. Methods: The charts revIewed will Include 25 subJects who
have been treated wIth Regranex (becaplermln) and 25 subJects who have not received Regranex (becaplermln) for the
treatment of wounds.
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PLEASE NOTE:
Only Information pertinent to your request to utilize human subjects In your pro·
ject or activity should be Included on this form. Where appropriate attach sections from your proposal (If seeking outside
funding).

2. PROTOCOL: (Describe procedures to which humans will be subjected. Use additional pages If necessary.)
SUBJECTS: 50 charts will be used from Ainu. 25 charts will Include subjects who have received Regranex (becaplermln) and 25 charts will
Include subjects who have not received Regranex (becaplermln) and have similar medical backgrounds such as diabetes, peripheral neuropathy and
any other conditions which would effect healing time of wounds.
PROCEDURE:
These charts will be randomly selected from Medical Records at Ainu. Information being recorded will be from evaluations and treatments
which have already been completed by a health professional. Information will be taken from the Inldal evaluation, at I month, at 2 months and 3
months. It will Include Pain Level, Length, Width and Depth of wound and treatment procedure. I will be wing the attached form. See appendix
A page 6.
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3. BENEFITS: (Describe the benefits to the Individual or society.)
This swdy will help Inform HealthCare professionals about Regranex (becaplermln). The results will show how effective It has been In clinical use so
that HealthCare professionals can make educated decisions as to when to use this product.

4. RISKS: (Describe the risks to the subject and precautions that will be taken to minimize them. The concept of risk goes beyond physical risk
and Includes risks to the subject's dignity and self·respect, as wen as psycho-logical, emotional or behavioral risk. If data are collected
which could prove harmful or embarrassing to the subject If associated with him or her, then describe the methods to be used to Insure
the confidentiality of data obtained, Including plans for final disposition or destruction, debriefing procedures, etc.)
This Is a chart review and since treatments have already been completed, there are no physical risks to the patients.
To ensure confidentiality, Information will be anonymously coded and Individuals will not be personally Identified In any
publication. The Information collected wID be kept for 3 years In a locked cabinet In room 1531 of the University of
North Dakota Physical Therapy Department and then It will be destroyed.
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5. CONSENT FORM: A copy of the CONSENT FORM to be signed by the subject (If applicable) and/or any statement to be read to the
subject should be attached to this form. If no CONSENT FORM Is to be used, document the procedures to be used to assure that Infringement
upon the subject's rights will not occur.
Describe where signed consent forms will be kept and for what period of dme.
This Is a retrospective chart review and all padents may not be available for signed consent. All Informadon will be kept
confldendal. Padents will be given a code to ensure this and names will not be used during the publlcadon of this
Informadon.

6. For FULL IRB REVIEW forward a signed original and thirteen (I 3) copies of this completed form, and where applicable, thirteen (13) copies
of the proposed consent form, quesdonnalres, etc. and any suppordng documentation to:
Office of Research 8: Program Development
University of North Dakota
Grand Forks, North Dakota 58202·7134
On campus, mall to: Office of Research 8: Program Development, Box 7134, or drop It off at Room 105 Twamley HaD.
For EXEMPT or EXPEDITED REVIEW forward a signed original and a copy of the consent form, quesdonnalres, etc. and any suppordng
documentadon to one of the addresses above.
.

The policies and procedures on Use of Human Subjects of the University of North Dakota apply to all activities Involving use of Human Subjects
performed by personnel conducting such actlvldes under the auspices of the University. No actlvldes are to be Initiated without prior review and
approval as prescribed by the University's policies and procedures governing the use of human subjects.
SIGNATURES:

5/;)\

Date (

/q9

fo;1ffl
te

Training or Center Grant Director

Date
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7

STUDENT RESEARCHERS: As of June 4, 1997 (based on the recommendation of UND Legal
Counsel) the University of North Dakota IRB is unable to approve your project unless the following
"Student Consent to Release of Educational Record" is signed and included with your "Human Subjects
Review Form."

STUDENT CONSENT TO RELEASE OF EDUCATIONAL RECORD

1

Pursuant to the Family Educational Rights and Privacy Act of 1974, I hereby consent to the Institutional
Review Board's access to those portions of my educational record which involve research that I wish to
conduct under the Board's auspices. I understand that the Board may need to review my study data
based on a q~estion from a parti~ipant or under a random audit. T~e study to which this release pertains

Is

Evaluatlon of the effectlVenessof Regranex (becaplenmn) on the treatment of wounds

I understand that such information concerning my educational record will not be released except on the
condition that the Institutional Review Board will not permit any other party to have access to such
information without my written consent. I also understand that this policy will be explained to those
persons requesting any educational information and that this release will be kept with the study
documentation.

~{j6~

Dale

t

LJooJ
Signature of Student Researcher

•

Consent reqUIred by 20 U.S.c. 1232g.
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MEMORANDUM

To:

Melissa WoodIDave ReIling
University of North Dakota
Physical Therapy Department
Grand Forks. NO 58202

From:

Kevin I. Tveter. MD
Chair
Altru Health System IRE

Date:

June 11. 1999

Re:

Evaluation of the Effectiveness of Regranex (bccaplennin) on Treatment of Wounds

The above project was approved by me on June 10. 1999. and enclosed is a copy of the Research
Project Action Report. Please complete the enclosed Research Project Completiontrennination
Report when you have completed your project and retum to:
Eleanor Tveit
Administration
Altru Clinic
P. O. Box 6003
Gmnd Forks. NO 58206-6003
Thank you.

KlT/crt
Enc.

Altru Clinic - Main Clinic
1000 South Columbia Road _ P.O. Box 6003 _ Grand Forks. ND 58206-6003 _ 701-780-6000
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ALTRU HEALTH SYSTEM
APPROVAL TO CONouer RESEARCH STUDY
AT ALTRU HEALTH SYSTEM
Name: Melissa Wood
Address:

Date:

June 7, 1999

750 N. 43ni Street. #47B, Grand Forks, ND 58203

Telephone Numbers: Work._ _ _ _ _ _ _ _ Home 701-795-9285
Department/College :
Project Title :

Physical TheraID' Dept School of Medicine and Health Sciences, UND

Evaluation of the Effectiveness ofRegranex ffiecaplennin) on the Treatment of

Wounds

a
Your request to conduct the above named study at an Altru Health System fucility involving
employees or patients as participants, and/or requiring facility resources has been reviewed. The
following action has been taken:

L

Permission to conduct the study is granted

_ _ Permission to conduct the study will be granted upon completion of the
following:

_ _ Permission to conduct the study is denied for the following reason(s):

SIgnature

Date

WOI'IfI=earch\prmsufrm

~ ~ ~ ~ ~a,N2Ja.
(jj_t~<..

l'{'if
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~Altru
. " , . - Hhlilb SylmJ

Institutional Review Board
Research Project Action Report ·

Date:_ _--"'J".,un"'-'e"-1.:.:0~.....l1,:::9.:::;99~_ _ _ _ _ _ _ _ _ IRB #: _ _ _ _~PT~-....:O::....I:....:I"--_ _ _ _ _ _ _ _ _ _ __
Principal Investigator.

Melissa WoodlDave Reiling

Department:

Physical Therapy

Phone #: 795·9285

Address to which notice of approval should be sent: UND. Physical Therapy. Box 9037. Grand Forks ND 58202·9037
Research Coordinator. _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ Phone #:_ _ __
Project Title:_-=E~va5!!l~ua5!!t~io~n~o!.!..f.l!th.!.l:ewE::!ff~e~ct:!!iv~e2!n.!.l:e:=:ss~of:....:R~e~g~ra!:!.ln.:..l:e:,Qx.l.(~be::.lca~p~le:.wrm.,!.!.!,!Jin!.L.),:::0u.n..!.T.:.:re<.!:a!l!tm~en~t~o!.!..f..!.W~o!.!:!u~nd:!.:s~_ _ _ _ __

The above referenced project protocol and informed consent was reviewed by the Altru Health System Institutional
Board on
and the following action was taken: .
:

Revie~

..... .

Cl

Project approved. Next Scheduled review is on --:'-::-_-:-:---::::----=:::-:-:-=:-:=-===':"":"":_ _ _--:'-:-_~__~
If no date is ~]iven. then review will be required in 12 months. (See REMARKS SECTION for any special condition.)

Cl

Project approved. EXPEDITED REVIEW NO. _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __
Next scheduled review is on,_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __

~

Project approved. EXEMPT CATEGORY NO.-:--::-::~:-:::-:-:':4::_::'_::_::"::::'":_:_:_--------------No periodic review scheduled unless so stated in REMARKS SECTION.

Cl

Project approval deferred. (See REMARKS SECTION for further information.)

Cl

Project denied. (See REMARKS SECTION for further information.)

Cl

Amendment approved

Cl

Administrative change approved

Cl

Protocol revision approved

Cl

Revised consent form approved

Cl

Adverse event reviewed· Date of event._ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __
Other_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _- - - -

Cl

REMARKS:
Any changes in protocol, adverse occurrences or deaths in the course of the research project must be reported immediatel
to the IRS chairperson or the IRB office (780-6161).

Date._ _

'_~_,o_'_,q._~_ _ __

If the proposed project is to be part of a research activity funded by a federal agency, a special assurance statement or a
completed 596 Form may be required. Contact IRS office to obtain the required documents.
B41~70JULY97
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APPENDIXB

DATA COLLECTION TOOL
"Evaluation of the Effectiveness of REGRANEX (becaplermin) Gel 0.01% on the
Treatment of Wounds"
ID# _ _ _ _ __
Age _ _ _ _ __
Sex - - - - - Medical Diagnosis: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __

Past Medical History:_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __

Location ofwound(s) on body from Altru eval. form: _ _ _ _ _ _ _ _ _ _ _ __

Stage of wound (circle): I

IT

ITI

IV

Objective Information:
Initial Evaluation

1 month

2 month

3 month

PainLe'\e1
Length (head to toe)
WilMh (side to side)
Depth (deepest)
% Granulation
"beefy" red
Other % like
SIOU2h. Eschar

Treatment Procedure (Including cleansing and home program):
1. Circle:

Regranex

No Regranex

2. Dressing: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __
3. Cleansing: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __
4. Other: (ie: ROM, Elevation, OtherMedications)_ _ _ _ _ _ _ _ __
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APPENDIXC

Indicate location of skin
breakdownlwound by letter.
If more than 1 area,
letter each area.

12

.(Q)3
6

FRONT

LEFT

RIGHT

RIGHT FOOT

LEFT FOOT

RIGHT

e~Lj

BACK
RIGHT

LEFT
LEFT

LEFT

RIGHT

~~
STAGES FOR PRESSURE ULCERS ONLY: (If ulcer is covered with eschar, do not stage until eschar is removed.)
Stage 1: Nonblanchable
erythema of intact skin. the
heralding lesion of skin
ulceration. In individuals with
darker skin, discoloration of the
skin, warmth, edema,
induration or hardness may
also be indicators.

Stage II: Partial thickness skin
loss involving epidermis,
dermis or both. The ulcer is
superficial and presents
clinically as an abrasion, blister
or shallow crater.

Stage III: Full thickness skin
loss involving damage to or
necrosis 'of subcutaneous
tissue that may extend down
to, but not through, underlying
fascia. The ulcer presents
clinically as a deep crater with
or withbut undermining of
adjacent tissue.

Stage IV: Full thickness skin
loss with extensive destruction,
tissue necrosis. or damage to
muscle, bone or supporting
structures (Le., tendon, joint
capsule). Undermining and
sinus tracts also may be
associated with Stage IV
pressure ulcers.

Wound Etiology: Pressure Ulcer (Stage - see above): Leg Ulcer (Etiology: IF KNOWN):
Surgical Wound (Surgical Procedure): Skin tear: other

B.

A.

Size:

cm (L)
cm (W)
cm (0)

Size:

C.

cm (L)
cm (W)
cm (0)

O.

Size:

Oate: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __

cm (L)
cm (W)
cm (0)

Size:

_ _ cm (L)
_ _ cm(W)
cm (0)

Signature: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __

Medical Park & Associates '
Initial Wound Documentation Record

a!sd!!:u
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S01HlJ72·A JAN

ga

~

DATE/INITIALS
LOCATION OF WOUND/KEY LETTER

SKIN

Length (head to toe)

(Weekly)

Width (side to side)

*AII

Depth (deepest portion)
Measurements UnderminingfTunnel - location
in em.
(measure with applicator)
Exposed Tendon: YorN
Exposed Bone: Y or N
COLOR
% of Granulation "beefy" red
% of Epithelial "pearly" pink
% of Slough (yellow, gray or white)
% of Eschar (thick, black)
DRAINAGE
Sanguinous
Serous
Sero-Sang
Purulent - COLOR
Describe type and amount of dressing saturated
ODOR
None, Mild, Foul (present after cleansing)
PERI·WOUND SKIN CONDmON
Intac!
Red (Erythema)
White
Abrased
Purple
Gray
Dry
Macerated
Edematous
Widest Point of Induration
Location of Induration (12, 3, 6, 9 o'clock)
CLEANSING ROUTINE:

TREATMENT (Describe type of dressing in detail)

PATIENT'S PERCEPTION OF PAIN
(Scale of 0 to 10) 0 = None
10 = Greatest

Initials:

Signature:

Initials:

Signature:

Initials:

Signature:

Initials:

Signature:

CHome Home SeNicu

CAItN Hospital
CAItN Heann Inlli1lllt
CAIIN Clinic

. Wound Care Flowsheet

~df!.ru
6011~371-FS JUNE 98
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